Cambrex High Point Site Clears FDA, PMDA, TGA Inspections for API Manufacturing
- Cambrex's High Point, North Carolina facility completed Pre-Approval Inspections from FDA, PMDA, and TGA, enabling commercial API manufacturing for US, Japan, and Australia markets.
- The site is purpose-built for lower-volume commercial production of orphan drugs, precision medicines, and specialized therapies targeting smaller patient populations.
- High Point becomes Cambrex's newest commercial manufacturing site within its global network, complementing ongoing capacity expansion in Iowa and Milan.
Operational Impact
High Point's multi-agency clearance adds specialized, lower-volume API capacity to Cambrex's commercial network, enabling faster commercial supply pathways for orphan and precision medicine sponsors seeking flexible manufacturing partners.
Source: Contract Pharma Breaking News RSS
Integrated GMP Operating Models Reshape Outsourced Manufacturing for Emerging Biopharma
- Adam Bartley examines how integrated GMP operating models are creating a middle path between in-house manufacturing and full CDMO outsourcing for emerging biopharma companies.
- Cleanroom hosting paired with quality systems, operational expertise, and strategic partnerships enables emerging companies to execute manufacturing without building dedicated facilities.
Operational Impact
CDMO directors should assess whether hybrid cleanroom-hosting partnerships with embedded quality and operational support represent a new competitive service tier that could capture emerging-biopharma manufacturing demand currently split between in-house builds and traditional outsourcing.
Source: Pharmaceutical Executive RSS